24 studies found for:    Open Studies | copd | United States, North Carolina
Show Display Options
Rank Status Study
1 Recruiting Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
Conditions: COPD;   COPD Exacerbation;   Lung Diseases;   Respiratory Disorders;   Pulmonary Disease;   Chronic Obstructive Lung Diseases;   Chronic Obstructive Airway Disease
Interventions: Drug: Roflumilast;   Drug: Placebo
2 Recruiting Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD
Conditions: COPD;   Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide;   Drug: Placebo
3 Recruiting Evaluate Safety of TI in Diabetic Subjects With Moderate Obstructive Pulmonary Disease (Asthma and COPD)
Conditions: Diabetic Type 1 With Asthma or COPD;   Diabetic Type 2 With Asthma or COPD;   Type 1 Diabetes;   Type 2 Diabetes;   Indeterminate Obstructive Lung Disease
Interventions: Drug: Technosphere Insulin;   Drug: Usual Care
4 Recruiting Study of COPD Subgroups and Biomarkers
Conditions: COPD;   Chronic Obstructive Pulmonary Disease;   Chronic Bronchitis;   Emphysema
Intervention:
5 Recruiting Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 1;   Drug: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 2;   Drug: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) Dose 3;   Drug: Budesonide metered dose inhaler (BD MDI);   Drug: Formoterol fumarate metered dose inhaler (FF MDI)
6 Recruiting Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Placebo
7 Recruiting Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Benralizumab Arm C;   Drug: Placebo
8 Recruiting Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Conditions: Emphysema;   Chronic Obstructive Pulmonary Disease (COPD);   Cystic Fibrosis;   Pulmonary Fibrosis;   Bronchiectasis;   Sarcoidosis;   Pulmonary Hypertension;   Alpha-1 Antitrypsin Deficiency
Interventions: Procedure: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™;   Device: STEEN Solution™
9 Recruiting Evaluation of FeNO During and Following Acute COPD Exacerbation
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Device: NIOX MINO®
10 Recruiting Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
Condition: COPD Patients
Interventions: Drug: Symbicort;   Drug: Formoterol turbohaler;   Other: Placebo for Symbicort pMDI;   Other: Placebo for Formoterol Turbohaler
11 Recruiting Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis
Conditions: Chronic Obstructive Pulmonary Disease;   COPD;   Chronic Bronchitis
Intervention: Other: Inhaled HS home treatment
12 Recruiting Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol;   Drug: Vilanterol
13 Recruiting Imaging Regional Lung Defect Severity
Condition: COPD
Interventions: Drug: Perfluorinated Gas/Oxygen Mixture;   Other: High Resolution CT of the Chest
14 Recruiting Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Mepolizumab;   Drug: Placebo
15 Recruiting Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Mepolizumab;   Drug: Placebo
16 Recruiting Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease (The Long-term Oxygen Treatment Trial [LOTT])
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Behavioral: Supplemental oxygen therapy
17 Recruiting A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate (FF);   Drug: vilanterol (VI);   Drug: umeclidinium bromide (UMEC)
18 Recruiting Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate;   Drug: Vilanterol
19 Recruiting Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF;   Drug: UMEC;   Drug: VI
20 Recruiting Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Conditions: Asthma;   Chronic Obstructive Pulmonary Disease;   Interstitial Lung Disease;   Cystic Fibrosis;   Pulmonary Hypertension
Intervention: Drug: Xenon

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years